20-05-2025
AUA 2025: Practice Impact of New mPC Data
Mohammad Mahmoud, MD, recalls how the AUA 2025 meeting in Las Vegas was an exciting and informative experience, especially regarding the management of metastatic prostate cancer. As a practicing urologist, Dr Mahmoud found the metastatic prostate cancer course particularly valuable for its practical updates on therapeutics like apalutamide and the importance of dose adjustments to reduce toxicity.
He notes that the emphasis on genetic testing for patients with de novo metastatic disease and the emerging role of PARP inhibitors reinforced the need for personalized treatment approaches. Additionally, discussions around triplet therapy and the growing role of prostate-specific membrane antigen in both diagnostics and treatment are set to impact clinical decisions and tumor board discussions in meaningful ways.
